DOJ Loosens Cannabis Product Restrictions in Policy Shift

The Justice Department has relaxed enforcement restrictions on certain marijuana products, marking another incremental step in the federal government's evolving cannabis policy framework. This administrative adjustment comes as the DEA continues its review process for rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act.

The policy modification reflects growing federal recognition of cannabis market realities, particularly as 38 states have legalized medical marijuana and 23 states permit adult-use sales. Multi-state operators like Curaleaf (CURLF), Trulieve (TCNNF), and Green Thumb Industries (GTBIF) continue expanding operations despite federal prohibition, generating billions in annual revenue while navigating complex compliance requirements.

This enforcement shift could reduce operational uncertainty for cannabis companies operating in state-legal markets. Federal agencies have increasingly adopted hands-off approaches toward compliant state programs, but formal policy clarifications provide additional regulatory comfort for institutional investors and banking partners who remain cautious about cannabis exposure.

The timing aligns with broader federal cannabis policy momentum, including ongoing rescheduling discussions and congressional debates over banking reform through the SAFER Banking Act. Cannabis companies face effective tax rates exceeding 70% due to Section 280E restrictions, which rescheduling could partially address by allowing standard business deductions.

While incremental, these administrative changes contribute to the gradual normalization of cannabis policy at the federal level. Investors continue monitoring regulatory developments closely, as federal reform remains the primary catalyst for unlocking institutional capital and enabling interstate commerce that could reshape the fragmented state-by-state market structure currently constraining industry growth.